From July 1, 2022 to September 24, 2022, the company has repurchased 14,499,918 shares, representing 0.73% for CNY 131.9 million. With this, the company has completed the repurchase of 15,699,918 shares, representing 0.78% for CNY 143.57 million under the buyback announced on June 15, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 CNY | +0.20% | -0.20% | -6.74% |
May. 15 | Tonghua Dongbao Pharmaceutical Launches Phase 1 Trial for Diabetes Injection in China | MT |
May. 10 | Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.74% | 2.75B | |
-3.20% | 90.45B | |
+3.95% | 41.45B | |
-10.51% | 33.57B | |
+60.58% | 25.73B | |
-20.09% | 14.73B | |
-8.92% | 12.82B | |
-11.46% | 11.7B | |
-43.05% | 11.44B | |
+5.17% | 8.79B |
- Stock Market
- Equities
- 600867 Stock
- News Tonghua Dongbao Pharmaceutical Co., Ltd.
- Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.